Role of a Clinical Research Organization in Accelerating Drug Development

A strong growth is being witnessed in the field of biotechnology and pharmaceutical product development. Similarly, there is an accompanying rise in the demand for capability and experience in the execution and organization of clinical studies. Both small and mid-sized pharmaceutical and biotech firms keep searching for novel means to enhance return on investment (ROI) and earning prospects. Here, a clinical research organization (CRO) can help them in accomplishing their goals and requirements.

The majority of biotech and pharmaceutical establishments have many products under development, which are indicated for rare and critical diseases. A CRO, also known as contract research organization, assists these companies in cutting down their clinical development lifecycle and employing robust strategic planning.

At every phase of growth, biotechnology firms require particular things to taste success, such as a powerful technological base, financial resources, and an efficient clinical development plan. Since there is no problem in fulfilling the first two requirements, the ultimate success of a drug depends upon the development of a safe and effective product for the use of humankind as established through clinical studies. Phase I through phase IV clinical trials are conducted under the direction of the US FDA to examine the safety profile and effectiveness of a drug in a clinical setup. Achieving successful clinical studies is very crucial. There is the need to make planning for the best possible clinical development strategy and execute that strategy properly.

In this juncture, clinical or contract research organizations can prove to be extremely helpful partners for biotech and pharmaceutical organizations. Forging a partnership with or outsourcing to a competent clinical research organization having experience in drug development can offer an advantage from strategic point of view. Consequently, these organizations can witness acceleration in drug development and reduction in overall costs while going through the development and approval procedure of a novel drug or medical device.

The procedure of organizing clinical studies with biological products is principally identical to that for any pharma product. Nevertheless, studies with these products create diverse demanding situations in terms of designing trial, recruiting patients and procuring supplies. Some additional difficulties also come in the form of inadequate resources and a clash between science and management focus. That’s why pharmaceutical and biotech companies outsource their clinical development to a qualified contract research organization.

An expert clinical research organization is capable of understanding the problem of inadequate resources and making use of its assets to deal with this conce
successfully. It boasts experience required to work with new and complicated remedies, particularly products in fresh, untried classes of drug. A competent CRO also has experience in executing and receiving approval for challenging programs quickly. You can expect a contract research organization to respect and share your corporate culture and ethics as well.